SCHEMBL234869

SCHEMBL234869

COC(/C=C(\C)CCC=C(C)C)OC

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
ALOX15 P16050 3/20 0.48
MEN1 O00255 2/20 0.48
CYP3A4 P08684 2/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
UGT1A1 P22309 1/20 0.47
SQLE Q14534 4/20 0.45
KDM4E B2RXH2 2/20 0.44
ATM Q13315 1/20 0.44
FNTA P49354 2/20 0.43
FNTB P49356 2/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234870 1.00 KMT2A (0.52) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL12285662 1.00 KMT2A (0.52) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL19183172 0.88 KMT2A (0.41) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL28245336 0.84 KMT2A (0.48) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL5604622 0.82 FNTA (0.58) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL5604687 0.82 FNTA (0.58) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL5604249 0.82 FNTA (0.58) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL5604645 0.82 FNTA (0.58) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL14867331 0.82 KMT2A (0.50) KMT2AALOX15MEN1CYP3A4ALDH1A1
SCHEMBL14548113 0.82 KMT2A (0.50) KMT2AALOX15MEN1CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559703-B2 Fragrance composition GIVAUDAN SA (CH) 2026-02-24 US claimed
EP-4695016-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2026-02-18 EP claimed
WO-2025202258-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2025-10-02 WO claimed
EP-4519404-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN Firmenich SA (CH) 2025-03-12 EP claimed
CN-119403908-A Method for enhancing psychological performance and composition for use in the method 弗门尼舍有限公司 2025-02-07 CN claimed
WO-2024213507-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-10-17 WO claimed
EP-4446001-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2024-10-16 EP claimed
WO-2023247604-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN FIRMENICH SA (CH) 2023-12-28 WO claimed
EP-4257663-A1 FOOD CONTACT SURFACE SANITIZING LIQUID The Procter & Gamble Company (US) 2023-10-11 EP claimed
US-20230151305-A1 FRAGRANCE COMPOSITION SA, GIVAUDAN (CH) 2023-05-18 US claimed
WO-2016049398-A1 FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049407-A1 ABSORBENT ARTICLE COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
US-20160090557-A1 SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US claimed
WO-2016049395-A1 PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
US-20160090555-A1 CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US claimed
US-20080311054-A1 Compositions and Methods to Counteract Oral Malodour GIVAUDAN SA (CH) 2008-12-18 US claimed
US-20080247966-A1 Compositions and Methods to Counteract Oral Malodour GIVAUDAN SA (CH) 2008-10-09 US claimed
EP-1937365-A1 COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR Givaudan SA (CH) 2008-07-02 EP claimed
WO-2007025402-A1 COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR GIVAUDAN SA (CH) 2007-03-08 WO claimed
US-6844302-B1 Encapsulated flavor and fragrance INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2005-01-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311054-A1 Compositions and Methods to Counteract Oral Malodour TAS2R60, TAS2R40, LPO KMT2A 3919/4885ALOX15 49/4885MEN1 2793/4885
US-12559703-B2 Fragrance composition DHCR24, OPRD1, OR10J3 KMT2A 2244/4885ALOX15 40/4885MEN1 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.